Importance Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalizations.
Objective To describe the epidemiology and burden of RSV-associated hospitalizations …

Background Despite passive immunization with palivizumab to select high-risk children
under two years of age, the health and economic burden of respiratory syncytial virus (RSV) …

Background and objective To assess the cost-utility of palivizumab versus no prophylaxis in
preventing severe respiratory syncytial virus (RSV) infection in Canadian moderate-to-late …

• Respiratory syncytial virus (RSV) is the leading cause of hospital admission for acute
respiratory infection in young infants.• Nirsevimab is a neutralizing longacting monoclonal …

Objective To evaluate the effectiveness of two palivizumab programmes targeting high-risk
infants, defined by prematurity, diagnosis of comorbidities and geography, and assess …

The introduction of nirsevimab (a respiratory syncytial virus [RSV] monoclonal antibody that
can protect for minimum 5 months with a single dose) and RSV maternal vaccines to protect …

Purpose Evaluate parental knowledge of respiratory syncytial virus (RSV) and other
respiratory infections in preterm infants. Design Survey. Sample Five hundred and eighty …

Respiratory syncytial virus (RSV) is a leading cause of morbidity and hospitalization in
young children, and prevention is the primary management strategy. At present …

• Le nirsévimab est un anticorps monoclonal neutralisant à longue durée d'action qui
prévient l'infection par le VRS en bloquant la protéine de surface F dans sa conformation …